While genomic studies have shown that the KRAS pathway plays a key role in several gynecological cancers, the exact mechanism of tumorigenesis involving KRAS mutations has been mostly investigated in studies focusing on endometrial cancer and low-grade ovarian cancer. This evidence concerns the gene KRAS and female reproductive organ cancer.